
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is poised for success as a promising player in the oncology market due to its strong sales and potential FDA approvals for their portfolio of new products that target various mechanisms of action in cancer treatment. With a focused pipeline and a solid financial standing, the company is receiving positive ratings from analysts and shows potential for long-term value creation and growth.
Bears say
BeOne Medicines is a holding company with a negative outlook due to its narrow focus on oncology treatments and dependence on a single product, BRUKINSA, for the majority of its revenue. The recent positive results and guidance raise are positive indicators, but the potential near-term approvals of sonrotoclax and BGB-16673 for r/r MCL and CLL, respectively, are not yet guaranteed and have not been factored into revenue estimates. Additionally, the company's solid tumor pipeline is still in early stages, and with the deprioritization of several early-stage programs, BeOne Medicines may face challenges in diversifying its portfolio.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares